Assessment of hydroxychloroquine maculopathy after cessation of treatment: An optical coherence tomography and multifocal electroretinography study

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 2993-2999

  Moschos, Marilita M ^a   Nitoda, Eirini ^a   Chatziralli, Irini P ^a   Gatzioufas, Zisis ^b   Koutsandrea, Chryssanthi ^a   Kitsos, George ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Swiss Eye Research Foundation   (Switzerland)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Hydroxychloroquine; Multifocal electroretinography; Optical coherence tomography; Toxic retinopathy; Visual acuity

Indexed keywords

HYDROXYCHLOROQUINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DRUG WITHDRAWAL; ELECTRORETINOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MULTIFOCAL ELECTRORETINOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; RETINA MACULOPATHY; RETINAL CENTRAL RESPONSE; RETINAL PERIPHERAL RESPONSE; RETINAL THICKNESS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ACUITY; COMPLICATION; HEMISPHERIC DOMINANCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; PATHOLOGY; RETINA; RETINA MACULA LUTEA; RETINAL DISEASES;

ELECTRORETINOGRAPHY; FEMALE; FUNCTIONAL LATERALITY; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MACULA LUTEA; MALE; MIDDLE AGED; RETINA; RETINAL DISEASES; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 84933055964     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S81303     Document Type: Article

References (37)

1. Rynes RI. Antimalarial drugs in the treatment of rheumatological diseases. Br J Rheumatol. 1997;36(7):799-805.
2. Casado E, Gratacós J, Tolosa C, et al. Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients. Ann Rheum Dis. 2006;65(3):385-390.
3. Stein M, Bell MJ, Ang LC. Hydroxychloroquine neuromyotoxicity. J Rheumatol. 2000;27(12):2927-2931.
4. Costedoat-Chalumeau N, Hulot JS, Amoura Z, et al. Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. Rheumatology (Oxford). 2007;46(5):808-810.
5. Cansu DU, Korkmaz C. Hypoglycaemia induced by hydroxychloroquine in a non-diabetic patient treated for RA. Rheumatology (Oxford). 2008;47(3):378-379.
6. Makin AJ, Wendon J, Fitt S, Portmann BC, Williams R. Fulminant hepatic failure secondary to hydroxychloroquine. Gut. 1994;35(4):569-570.
7. Cohen PR. Hydroxychloroquine-associated hyperpigmentation mimicking elder abuse. Dermatol Ther (Heidelb). 2013;3(2):203-210.
8. Yam JC, Kwok AK. Ocular toxicity of hydroxychloroquine. Hong Kong Med J. 2006;12(4):294-304.
9. Geamănu Pancă A, Popa-Cherecheanu A, Marinescu B, Geamănu CD, Voinea LM. Retinal toxicity associated with chronic exposure to hydroxychloroquine and its ocular screening. J Med Life. 2014;7(3):322-326.
10. Palma Sánchez D, Rubio Velazquez E, Soro Marín S, Reyes García R. Retinal toxicity due to antimalarials: frequency and risk factors. Reumatol Clin. 2013;9(5):259-262.
11. Marmor MF. New American Academy of Ophthalmology recommendations on screening for hydroxychloroquine retinopathy. Arthritis Rheum. 2003;48(6):1764.
12. Karkanová M, Matusková V, Vlková E, Dosková H, Uhmannová R. [The ERG contribution in early diagnosis of chloroquine and hydroxychloroquine maculopathy]. Cesk Slov Oftalmol. 2010;66(2):62-66. Czech.
13. Lai WW, Lam DS. Chloroquine-induced bull's eye maculopathy. Hong Kong Med J. 2005;11(1):55-57.
14. So SC, Hedges TR, Schuman JS, Quireza ML. Evaluation of hydroxychloroquine retinopathy with multifocal electroretinography. Ophthalmic Surg Lasers Imaging. 2003;34(3):251-258.
15. Rodríguez-Hurtado FJ, Sáez-Moreno JA, Rodríguez-Ferrer JM. Ocular toxicity and functional vision recovery in a patient treated with hydroxychloroquine. Reumatol Clin. 2015;11(3):170-173.
16. Aliferis K, Mermoud C, Safran AB. [Multifocal electroretinography in follow up of patients treated with hydroxychloroquine]. J Fr Ophtalmol. 2011;34(7):468-475. French.
17. Melles RB, Marmor MF. Pericentral retinopathy and racial differences in hydroxychloroquine toxicity. Ophthalmology. 2015;122(1):110-116.
18. Kellner U, Renner AB, Tillack H. Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine. Invest Ophthalmol Vis Sci. 2006;47(8):3531-3538.
19. Lyons JS, Severns ML. Detection of early hydroxychloroquine retinal toxicity enhanced by ring ratio analysis of multifocal electroretinography. Am J Ophthalmol. 2007;143(5):801-809.
20. Moschos MN, Moschos MM, Apostolopoulos M, Mallias JA, Bouros C, Theodossiadis GP. Assessing hydroxychloroquine toxicity by the multifocal ERG. Doc Ophthalmol. 2004;108(1):47-53.
21. Nebbioso M, Livani ML, Steigerwalt RD, Panetta V, Rispoli E. Retina in rheumatic diseases: standard full field and multifocal electroretinography in hydroxychloroquine retinal dysfunction. Clin Exp Optom. 2011;94(3):276-283.
22. Maturi RK, Yu M, Weleber RG. Multifocal electroretinographic evaluation of long-term hydroxychloroquine users. Arch Ophthalmol. 2004;122(7):973-981.
23. Browning DJ. Impact of the revised american academy of ophthalmology guidelines regarding hydroxychloroquine screening on actual practice. Am J Ophthalmol. 2013;155(3):418.e-428.e.
24. Marmor MF. Comparison of screening procedures in hydroxychloroquine toxicity. Arch Ophthalmol. 2012;130(4):461-469.
25. Neubauer AS, Samari-Kermani K, Schaller U, Welge-Lübetaen U, Rudolph G, Berninger T. Detecting chloroquine retinopathy: electro-oculogram versus colour vision. Br J Ophthalmol. 2003;87(7):902-908.
26. Heravian J, Saghafi M, Shoeibi N, Hassanzadeh S, Shakeri MT, Sharepoor M. A comparative study of the usefulness of color vision, photostress recovery time, and visual evoked potential tests in early detection of ocular toxicity from hydroxychloroquine. Int Ophthalmol. 2011;31(4):283-289.
27. Cukras C, Huynh N, Vitale S, Wong WT, Ferris FL 3rd, Sieving PA. Subjective and objective screening tests for hydroxychloroquine toxicity. Ophthalmology. 2015;122(2):356-366.
28. Lai TY, Ngai JW, Chan WM, Lam DS. Visual field and multifocal electroretinography and their correlations in patients on hydroxychloroquine therapy. Doc Ophthalmol. 2006;112(3):177-187.
29. Marmor MF, Melles RB. Disparity between visual fields and optical coherence tomography in hydroxychloroquine retinopathy. Ophthalmology. 2014;121(6):1257-1262.
30. Anderson C, Blaha GR, Marx JL. Humphrey visual field findings in hydroxychloroquine toxicity. Eye (Lond). 2011;25(12):1535-1545.
31. Tanga L, Centofanti M, Oddone F, et al. Retinal functional changes measured by frequency doubling technology in patients treated with hydroxychloroquine. Graefes Arch Clin Exp Ophthalmol. 2011;249(5):715-721.
32. Jivrajka RV, Genead MA, McAnany JJ, Chow CC, Mieler WF. Microperimetric sensitivity in patients on hydroxychloroquine (Plaquenil) therapy. Eye (Lond). 2013;27(9):1044-1052.
33. Rodriguez-Padilla JA, Hedges TR 3rd, Monson B, et al. High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathy. Arch Ophthalmol. 2007;125(6):775-780.
34. Korah S, Kuriakose T. Optical coherence tomography in a patient with chloroquine-induced maculopathy. Indian J Ophthalmol. 2008;56(6):511-513.
35. Pasadhika S, Fishman GA. Effects of chronic exposure to hydroxychloroquine or chloroquine on inner retinal structures. Eye (Lond). 2010;24(2):340-346.
36. Marmor MF, Hu J. Effect of disease stage on progression of hydroxychloroquine retinopathy. JAMA Ophthalmol. 2014;132(9):1105-1112.
37. Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF; American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118(2):415-422.